In line with our findings, knockdown of ARID1A in HCC cells did not alter susceptibility to sorafenib in vitro, implying that the increased susceptibility to sorafenib is not a direct effect of ARID1A loss in the HCC cells, rather it is due to the effect on angiogenesis. Here, ARID1A is linked to hepatocellular carcinoma.